Inventor · disambiguated record
Michael G. Nicholson
Also filed as: NICHOLSON MICHAEL G
18 granted patents·36 pending applications·207 citations·filing 2003–2025
95Inventor score
Top patents by PatentIndex Score
54 records- 0198US9889161B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2017·Granted Feb 13, 2018·27 cites·4 claims
- 0298US9889160B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2017·Granted Feb 13, 2018·65 cites·9 claims
- 0397US10093900B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Oct 9, 2018·15 cites·9 claims
- 0497US9993501B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Jun 12, 2018·11 cites·13 claims
- 0597US9993502B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Jun 12, 2018·16 cites·13 claims
- 0697US9969975B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted May 15, 2018·13 cites·9 claims
- 0797US9950010B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Apr 24, 2018·14 cites·8 claims
- 0897US9950011B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Apr 24, 2018·14 cites·8 claims
- 0994US10093899B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Oct 9, 2018·8 cites·9 claims
- 1093US10799535B2Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2016·Granted Oct 13, 2020·5 cites·5 claims
- 1191US10603363B2Treatment of retinitis pigmentosa using engineered meganucleasesPREC BIOSCIENCES INC·Filed 2016·Granted Mar 31, 2020·3 cites·10 claims
- 1291US2025121039A1Treatment of retinitis pigmentosa using engineered meganucleasesPREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1387US9822381B2Methods and products for producing engineered mammalian cell lines with amplified transgenesPREC BIOSCIENCES INC·Filed 2015·Granted Nov 21, 2017·2 cites·11 claims
- 1487US2024002796A1Genetically-modified cells comprising a modified human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 1587US2024238387A1Treatment of retinitis pigmentosa using engineered meganucleasesPREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 1686US2024156919A1Dystrophin gene exon deletion using engineered nucleasesPREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 1786US2024228992A1Fusion molecules of rationally-designed dna-binding proteins and effector domainsUNIV DUKE·Filed 2023·Application pending·0 cites
- 1885US2024382526A1Nucleic acids encoding engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1982US2022135945A1Genetically-modified cells comprising a modified human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2082US2022145251A1Genetically-modified cells comprising a modified human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2179US11268065B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2021·Granted Mar 8, 2022·0 cites·17 claims
- 2279US2024052373A1Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin genePREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2379US2022143155A1Treatment of retinitis pigmentosa using engineered meganucleasesPREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2478US2022333137A1Methods and products for producing engineered mammalian cell lines with amplified transgenesPREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2578US2023193318A1Self-limiting viral vectors encoding nucleasesPREC BIOSCIENCENS INC·Filed 2022·Application pending·0 cites
- 2677US2021332338A1Fusion molecules of rationally-designed dna-binding proteins and effector domainsUNIV DUKE·Filed 2021·Application pending·0 cites
- 2777US2025152679A1Dystrophin gene exon deletion using engineered nucleasesPREC BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 2876US2025346874A1Fusion molecules of rationally-designed dna-binding proteins and effector domainsUNIV DUKE·Filed 2025·Application pending·0 cites
- 2975US2022152112A1Nucleic acids encoding engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3074US2021000928A1Treatment of retinitis pigmentosa using engineered meganucleasesPREC BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3174US2020109384A1Fusion molecules of rationally-designed dna-binding proteins and effector domainsUNIV DUKE·Filed 2019·Application pending·0 cites
- 3273US11266693B2Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2020·Granted Mar 8, 2022·0 cites·9 claims
- 3373US2021145940A1Dystrophin gene exon deletion using engineered nucleasesPREC BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3472US10758595B2Treatment of retinitis pigmentosa using engineered meganucleasesPREC BIOSCIENCES INC·Filed 2020·Granted Sep 1, 2020·0 cites·17 claims
- 3572US2019194616A1Genetically-modified cells comprising a modified human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 3672US2019249199A1Methods and products for producing engineered mammalian cell lines with amplified transgenesPREC BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3770US7083728B2Method for treating sludge using recycleVIRO INTERNAT CORP N·Filed 2003·Granted Aug 1, 2006·14 cites·9 claims
- 3868US2019365870A1Dystrophin gene exon deletion using engineered nucleasesPREC BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3967US2018163233A1Methods and products for producing engineered mammalian cell lines with amplified transgenesPREC BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 4067US2020308602A1Self-limiting viral vectors encoding nucleasesPREC BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4167US2019269762A1Dystrophin gene exon deletion using engineered nucleasesPREC BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 4266US2021032664A1Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin genePREC BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4366US2022193267A1Engineered nucleases useful for treatment of hemophilia aPREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4466US2018023065A1Fusion molecules of rationally-designed dna-binding proteins and effector domainsUNIV DUKE·Filed 2017·Application pending·0 cites
- 4564US2014010797A1Fusion Molecules of Rationally-Designed DNA-Binding Proteins and Effector DomainsUNIV DUKE·Filed 2012·Application pending·0 cites
- 4663US10662440B2Self-limiting viral vectors encoding nucleasesPREC BIOSCIENCES INC·Filed 2016·Granted May 26, 2020·0 cites·21 claims
- 4761US2014179005A1Methods and Products for Producing Engineered Mammalian Cell Lines With Amplified TransgenesPREC BIOSCIENCES INC·Filed 2013·Application pending·0 cites
- 4861US2015315556A1Fusion Molecules of Rationally-Designed DNA-Binding Proteins and Effector DomainsUNIV DUKE·Filed 2015·Application pending·0 cites
- 4959US2019017075A1Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin genePREC BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 5057US11278632B2Engineered nucleases useful for treatment of hemophilia APREC BIOSCIENCES INC·Filed 2017·Granted Mar 22, 2022·0 cites·16 claims
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Michael G. Nicholson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →